Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 35 for your search:

Cancer Type/Condition:  Ewing sarcoma/PNET
Stage/Subtype:  recurrent Ewing sarcoma/PNET
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Reduced Intensity Transplant Using Extracorporeal Photopheresis

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790

Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: BMT 0499 Solid, NCT00179816

Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021020, NCT00560235

Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 months to 35 years
Sponsor: NCI
Protocol IDs: 070206, 07-C-0206, NCT00923351

Phase II Pilot Study of Induction Chemotherapy Followed By Allogeneic/Syngeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk, Recurrent Pediatric Sarcoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 4 to 35
Sponsor: NCI
Protocol IDs: NCI-02-C-0259, NCT00047372

Phase II Study of Ecteinascidin 743 in Pediatric Patients With Recurrent or Refractory Soft Tissue Sarcomas or Ewing's Sarcoma Family of Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 21 (at time of diagnosis)
Sponsor: NCI
Protocol IDs: COG-ADVL0221, NCT00070109, ADVL0221

Phase II Study of Sequential Gemcitabine and Docetaxel in Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing’s Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 4 and over
Sponsor: NCI
Protocol IDs: SARC003, NCT00073983, NCI-04-C-0001, AEWS0421, MAYO-79-2003

Phase II Study of Umbilical Cord Blood as a Source of Hematopoietic Stem Cells for Transplantation in Children With Malignant or Non-Malignant Diseases

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: PSCI-2003-232, NCT00084695

10.

Radiation Therapy to Treat Musculoskeletal Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: RTSARC, NCT00186992

11.

Phase II Study of Intrathecal Iodine I 131 Monoclonal Antibody 3F8 in Patients With GD2-Expressing Central Nervous System or Leptomeningeal Neoplasms

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965

12.

Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187

13.

Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas

Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, NCT00592293

14.

A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed Osteosarcoma or Ewing's Sarcoma (Study P04720AM3)

Phase: Phase II
Type: Treatment
Status: Active
Age: 11 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P04720, NCT00617890

15.

A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent

Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP13-0707, EudraCT Number: 2007-006719-21, NCT00668148

16.

A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UMCC 2008.049, NCT00743509

17.

Phase II Study of Cixutumumab in Patients With Relapsed or Refractory Solid Tumors

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 months to 30 years
Sponsor: NCI
Protocol IDs: COG-ADVL0821, ADVL0821, NCT00831844

18.

A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.

Phase: Phase II
Type: Treatment
Status: Active
Age: 2 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NO21157, SARC011, NCT00642941

19.

Phase I Study of Interleukin-12 and Interleukin-2 in Patients With Refractory or Advanced Solid Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-00-C-0121, NCI-41, 41, NCT00020163

20.

Phase I Study of Ixabepilone in Young Patients With Refractory Solid Tumors (Closed to Accrual as of 10/4/2007) or Relapsed or Refractory Leukemia

Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: NCI-02-C-0031, 02-C-0031, 5425, NCI-5425, NCT00030108

21.

Phase I Study of Yttrium Y 90-DOTA-tyr3-Octreotide in Children With Advanced or Refractory Somatostatin Receptor-Positive Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI
Protocol IDs: UIHC-200008086, NCI-V02-1710, NCT00049023, 200008086

22.

Phase I Study of Intrathecal Iodine I 131 Monoclonal Antibody 8H9 in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MSKCC-03133, NCT00089245

23.

Phase I Study of Allogeneic Hematopoietic Stem Cell Transplantation in Young Patients With Relapsed or Refractory Solid Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: PSCI-20615, NCT00112645

24.

Phase I Study of Cediranib in Pediatric Patients With Refractory or Recurrent Extracranial Malignant Solid Tumors or Acute Myeloid Leukemia

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-06-C-0152, NCI-P6571, NCT00354848, ZENECA-D8480C00016

25.

Phase I Study of BB-10901 in Patients With Relapsed or Refractory Small Cell Lung Cancer, Other Pulmonary Tumors of Neuroendocrine Origin, Non-Pulmonary Small Cell Carcinoma, Metastatic Carcinoid Tumors, or Other CD56-Positive Solid Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IMMUNO-C10/IVB/002, IMMUNO-002, MDA-2004-0557, NCT00346385

Select All on Page

Help with Results

A Service of the National Cancer Institute